A61K31/7032

SKIN BARRIER COMPOSITION
20220031721 · 2022-02-03 · ·

The present invention provides a composition for topical administration of a polyhydroxy acid, such as lactobionate and especially zinc lactobionate, and low pH to an external body surface such as skin. The composition is designed to be highly effective in delivering low pH and zinc lactobionate across the layers of the skin to more effectively treat and prevent skin conditions involving a defective skin barrier such as eczema and severe dry skin.

SKIN BARRIER COMPOSITION
20220031721 · 2022-02-03 · ·

The present invention provides a composition for topical administration of a polyhydroxy acid, such as lactobionate and especially zinc lactobionate, and low pH to an external body surface such as skin. The composition is designed to be highly effective in delivering low pH and zinc lactobionate across the layers of the skin to more effectively treat and prevent skin conditions involving a defective skin barrier such as eczema and severe dry skin.

SKIN BARRIER COMPOSITION
20220031721 · 2022-02-03 · ·

The present invention provides a composition for topical administration of a polyhydroxy acid, such as lactobionate and especially zinc lactobionate, and low pH to an external body surface such as skin. The composition is designed to be highly effective in delivering low pH and zinc lactobionate across the layers of the skin to more effectively treat and prevent skin conditions involving a defective skin barrier such as eczema and severe dry skin.

PHARMACEUTICAL ANTI-INFECTIVE COMPOSITION FOR INHALATION
20170232029 · 2017-08-17 ·

An anti-infective composition for inhalation, containing, at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof; and an effective amount of a biofilm modifier which is a macrolide compound or salt thereof.

Phenylethanoid Glycoside Extract from Acanthus Ilicifolius L., Preparation Method thereof and Use as Anti-liver Injury Medicament

Provided are a phenylethanoid glycoside extract from the plant A. ilicifolius L., a preparation method thereof, and its use as an anti-liver injury medicament. The preparation method of the phenylethanoid glycoside extract comprises following steps: pulverizing dried whole plant Acanthus ilicifolius L. and passing through 20-30 mesh sieve to obtain Acanthus ilicifolius L. powder, adding 50%-95% ethanol solution whose mass is 8-20 times of the powder, soaking and extracting under reflux, filtering and collecting extract of the powder, and extracting a filter residue under reflux with 50%-95% ethanol solution whose mass is 8-10 times of the filter residue and collecting extract of the filter residue, combining, concentrating and subjecting to macroporous resin column chromatography, eluting successively by 10%, 30% and 50% ethanol solutions for four column volumes, respectively, collecting fraction eluted by the 50% ethanol solution and drying to obtain the phenylethanoid glycoside extract.

Phenylethanoid Glycoside Extract from Acanthus Ilicifolius L., Preparation Method thereof and Use as Anti-liver Injury Medicament

Provided are a phenylethanoid glycoside extract from the plant A. ilicifolius L., a preparation method thereof, and its use as an anti-liver injury medicament. The preparation method of the phenylethanoid glycoside extract comprises following steps: pulverizing dried whole plant Acanthus ilicifolius L. and passing through 20-30 mesh sieve to obtain Acanthus ilicifolius L. powder, adding 50%-95% ethanol solution whose mass is 8-20 times of the powder, soaking and extracting under reflux, filtering and collecting extract of the powder, and extracting a filter residue under reflux with 50%-95% ethanol solution whose mass is 8-10 times of the filter residue and collecting extract of the filter residue, combining, concentrating and subjecting to macroporous resin column chromatography, eluting successively by 10%, 30% and 50% ethanol solutions for four column volumes, respectively, collecting fraction eluted by the 50% ethanol solution and drying to obtain the phenylethanoid glycoside extract.

COMPOSITIONS COMPRISING AMINO ACIDS AND A FURTHER COMPONENT FOR THE SUPPLY OF AMINO ACIDS TO A MONOGASTRIC ANIMAL SUCH AS A HUMAN OR A PIG
20220264910 · 2022-08-25 ·

A composition comprising at least one amino acid, (ii) a controlled release lipid matrix, and optionally (iii) at least one acceptable pharmaceutical or food grade additive and/or excipient and a related method for the treatment of amino acid supply or protein deficiency in a monogastric subject, preferably a human subject or a pig, are disclosed as well as a feed or feed additive comprising the composition for a monogastric animal, preferably a pig.

COMPOSITIONS COMPRISING AMINO ACIDS AND A FURTHER COMPONENT FOR THE SUPPLY OF AMINO ACIDS TO A MONOGASTRIC ANIMAL SUCH AS A HUMAN OR A PIG
20220264910 · 2022-08-25 ·

A composition comprising at least one amino acid, (ii) a controlled release lipid matrix, and optionally (iii) at least one acceptable pharmaceutical or food grade additive and/or excipient and a related method for the treatment of amino acid supply or protein deficiency in a monogastric subject, preferably a human subject or a pig, are disclosed as well as a feed or feed additive comprising the composition for a monogastric animal, preferably a pig.

Glucocerebroside treatment of disease

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

Glucocerebroside treatment of disease

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.